Get started

Coronavirus (COVID-19)

$Enzc where do we go from here??? The chart broke down from our previous wedge, causing a wide broadening formation. We broke below the 0.618 fib level, would have liked to see a sustained volume shelf there creating a better support. Price will need to bounce from 0.1011 and close above that level or we will continue to see continued selling pressure. EXPECT ALOT OF VOLATILITY FOR THE REMAINDER OF DECEMBER! I still haven't sold a single share and will continue to aquire more every chance I get (seems more now than ever) Know your 50/30/20 rule! 50% of what a stock does is determined by what the overall market does 30% of what a stock does is determined by what the sector & industry group does 20% of the movement of the stock is determined by the analysis of the stock itself
OTC:ENZC
by OptionStonker
Omicron Weighs on Global StocksWe cautioned readers yesterday to exercise caution with stocks and this advice was warranted, as stocks have dipped further into negative territory. Global stocks have pushed lower with news of the first case of the Omicron strain of the Coronavirus was confirmed in the United States. We have broken through what appeared to be strong support at 4580, then 4564, taking out several levels below, and finally finding support at 4504, confirmed by a green triangle on the KRI. All of these levels we have discussed in the past, and we gave comments to yesterday's report keeping readers updated. The Kovach OBV is quite bearish, but we are currently seeing another meager attempt at a rally, which is currently facing resistance confirmed by a red triangle on the KRI at 4545, another one of our levels. From here it depends on how the markets will interpret this news further. A rally will have to break 4580 and cross the vacuum zone above for stocks to attempt a recovery. Further fallout could break 4504 and test the 4400's, with 4487 and 4462 being the next targets. We still advise caution in buying this dip as the fallout may persist, or we may see at least some volatility as markets jostle for footing.
FX:SPX500Short
by quantguy
1
$VIR entry PT 42-44 Long term Target PT 200HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $200 CEO of Covid antibody maker Vir Biotech says its treatment ‘stands up well’ to all variants KEY POINTS: - Vir Biotechnology CEO George Scangos said the monoclonal antibody Covid treatment it developed with GlaxoSmithKline “stands up well” to all variants. - The companies announced contracts to sell $1 billion worth of sotrovimab to the U.S. government. The FDA has already granted sotrovimab an emergency use authorization to treat mild to moderate Covid infections. - Though Scangos said the delta variant is “going to be with us for a while,” he added that sotrovimab could likely protect against new variants that emerge. Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
NASDAQ:VIRLong
by BADQOMOCAWGOWLD
Bitcoin Possible MoveI don't know what happened, but if it's related to my technical analysis of xrp it's pontetial to happen.. IF BTC IS BELOW $53K, WE WILL SEE BTC DROP TO $43K.. AND WE COULD SEE HIDDEN BULLISH DIVERGENCE (RSI) In my opinion, this is because short-term holders have taken a little profit to minimize their losses due to market doubts that are not ready to going up with the release of the new covid variant. Maybe I'm the only one who don't believe that btc will close above 85k last November.. and i think december there will be a price boost up.. #DYOR
BITFINEX:BTCUSD
by Enternity88
1
How to Trade Stocks as Omicron WeighsCoronavirus fears continue to weigh on stocks. In particular, the Moderna CEO predicts less effective vaccines for the Omicron variant, and this has sent stocks back to lows despite an attempt at a rally, yesterday. We made it as high as 4668, which we have identified as a new technical level, before falling back to lows, which appear to be holding for now, perhaps by a thread. A green triangle on the KRI does appear to be suggesting we are finding support here at 4580, but are not really seeing much of a bounce. If current levels don't hold, we could see support at 4564, 4545, or 4504. Watch for stocks to make another bounce and perhaps form a bear wedge with a lower bound at 4580 before cracking it. If we do catch a bid, then 4632 and 4649 need to be broken before we can consider higher levels again.
FX:SPX500
by quantguy
1
Gold Long EntryGold: After dropping down to the $1781 area yesterday evening, Gold managed to climb towards $1798 before consolidating. The RSI levels on the daily chart remain oversold, currently at the 8.32 levels. On the 1hr time frames the recent candles that have emerged show to have decent buying pressure. It looks like the price will move up from here at test the $1800-03 zone this week. Not only do the technical support this analysis but the growing concerns over the “Omicron” variant might persuade investors to move into the safe-haven gold, pushing price up.
OANDA:XAUUSDLong
by Orion-Markets
2
$IINN PT 9 and higherInspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
NASDAQ:IINNLong
by BADQOMOCAWGOWLD
1
$LGVN entry PT 25 Target PTs 43-49 and higherLongeveron stock is up by a multiple of 11 after the FDA gave a Rare Pediatric Disease designation for a heart medication last week. Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
NASDAQ:LGVNLong
by BADQOMOCAWGOWLD
1
$ISPC entry 14.65-16.15-ish Target PTs 29 and higheriSpecimen, Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables researchers to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
NASDAQ:ISPCLong
by BADQOMOCAWGOWLD
1
Will the ship change course? :)since March we have witnessed a sharp rise in the US30 index, its global trend is growing. We all think it will go and grow non-stop. When we look at the weekly chart we can clearly see that the strength of the index is gradually declining, we are witnessing its high susceptibility to new variants of the covid virus. In my opinion, the Covid virus is an ingenious virus that has completely opposite behavior from other viruses, it only perfects itself. He is getting more and more perfect. Can the situation from February and March 2020 be repeated, when the US30 experienced a sharp decline. It is naturally possible and necessary. The question is when will a new variant of the virus emerge that will drastically affect the global economy. I don't think this variant is actually the one that will push the ship to the bottom.
UShort
by DM2365
Moderna about to reclaim bullish Channel. Short-Term-BULLISH! Not financial advice! With the new corona variant spreading fear all over the world, PFE and MRNA are running. I think it's possible for MRNA to reclaim the bullish channel, aka the Bull-Trap that broke down, when PFE announced the Paxlovid-med. I got in MRNA way to late, now taking a risky trade, since MRNA gaps like crazy, and there's always the chance that it'll brake down to be traded at skipped price-levels. I think one should watch out for PFE announcing Paxlovid being effective against the omicron variant, which could lead a lot of investors to switch to PFE. Today I want to see MRNA reclaiming the bullish channel at $377,xx and hold within this channel. From there on, it's more than a 30% ride to the top of the channel. But this stock has done crazy things like this in the past. Depending on how fast MRNA manages to reclaim the top, the price correlates with the last ATH at $494,xx. I think, if it manages to get back at the center of the channel, it will be rejected at the old resistance at $463,xx first, settle a bit and then trying to break the $500. My plan is to sell at $463 and then watch how things develop. But remember if, you're not in it by now, it maybe is bad timing to get in at this pricelevel. Risk is way to high, because of the gaps. That is why I marked this trading strategy as Neutral. Good luck in the markets! Again, this is not financial advice!
NASDAQ:MRNA
by robvanhoven
PFE Pfizer to All Time HighIf you haven`t bought at my first call, when PFE was $40: Than you should know that Pfizer’s vaccine with BioNTech SE is on track to be the best-selling drug product on a yearly basis and received backing from a European regulatory panel on Thursday to expand its use into children as young as five. Still low PE Ratio (TTM) 15.42 Decent Forward Dividend & Yield 1.56 (2.89%) The stock jumped also on the promise of its antiviral pill! For me is a Buy even at this level!
NYSE:PFELong
by TopgOptions
1
USDJPY bearish scenario:On Friday USD/JPY consolidates the heaviest daily loss since March 2020, bouncing off a 13-day low. That happened after WHO termed Omicron as a “variant of concern”, Japan tightens border controls. Looking forward, the virus developments in the West will be particularly more important for the USD/JPY traders, which in turn highlights today’s speech from US President Joe Biden to update on the US reaction to the COVID-19 variant. Additionally, comments from Fed Chairman Jerome Powell will be observed closely for fresh impulse too. In this pair, technical analysis shows a technical figure Rising Wedge. The Rising Wedge broke through the support line on 27/11/2021. USDJPY is forming a bearish formation on a daily chart. If the price holds below this level, we will have a possible bearish price movement with a forecast for the next 18 days with a target of 111.29. According to the experts, your stop loss should be around 115.52 if you enter this position. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
Short
by legacyFXofficial
2
$BNTX^ $BNTX will announce if its possible to revise their current vaccine to accommodate the new strain in 2 weeks and could redesign its vaccine within 6 weeks, with an aim to distribute it within 100 days. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
NASDAQ:BNTXLong
by BADQOMOCAWGOWLD
1
$MRNAModerna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, Metagenomi, Inc., and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
NASDAQ:MRNALong
by BADQOMOCAWGOWLD
NRXP COVID-19 Vaccine Effectiveness Against Delta VariantNRx Pharmaceuticals announced that its BriLife COVID-19 Vaccine is Effectiveness Against Delta Variant. Information was released by Israel Institute for Biological Research. Since the pandemic isn`t over, there is a place in the market for new developers that have effective vaccines. I consider this a premium call, the upside i see here is 400%, or the 24usd resistance. NRXP 52 Week Range 4.07 - 76.99usd. Now the price is 6.75usd. Is this a buy or not? Market Cap of only 396.97Mil
NASDAQ:NRXPLong
by TopgOptions
1
VXUS near levels to add to positionVXUS is an ETF issued by Vanguard that seeks to track the FTSE Global All Cap ex US Index, which measures the investment return of stocks issued by companies located outside the United States. VXUS holds 7760 stocks, with net assets totaling $416.8 billion and an expense ratio of only 0.08% this ETF is extremely attractive for exposure to mostly large cap global equities. With the recent identification of a new variant of Covid the ETF's price has started to decline quite quickly. Viewing this ETF as a long term investment declines in price due to market panics are seen as excellent opportunities to purchase shares at reduced prices. As price declines I will continue to gradually increase the size of my position in this fund. Recent events have shown us that the perceived disruptions and negative effects of the Covid pandemic have not been nearly as detrimental to business as previously thought and so any undue panic simply represent an opportunity for patient, dispassionate investors to pick up bargains. *Not a recommendation to buy or sell*
NASDAQ:VXUSLong
by MarkE
2